Vection Technologies (ASX:VR1) - Managing Director, Gianmarco Biagi
Managing Director, Gianmarco Biagi
Source: Vection Technologies
The Market Online - At The Bell

Join our daily newsletter At The Bell to receive exclusive market insights

  • Software company Vection Technologies (VR1) has launched a healthcare and pharma solutions division as part of its international growth strategy
  • The division will be made up of six professionals led by Dr Carlo Centemeri, who has senior experience in the Italian healthcare and pharmaceutical space
  • Through the 60-per-cent-owned division, Vection will leverage its core technologies to develop innovative educational and communication models
  • The launch follows recent deals in the agri-food and arts and culture markets — demonstrating Vection’s commitment to expansion
  • Vection expects opportunities for its new division to start coming to fruition from next month
  • Company shares are up 3.13 per cent and trading at 9.9 cents

Vection Technologies (VR1) has launched its healthcare and pharma solutions division which it will own a 60 per cent stake in.

The launch of this division aligns with Vection’s international growth strategy and expands its footprint into the health and nutraceutical sectors.

Vection will partner with a six-person team led by Dr Carlo Centemeri who has senior experience in the healthcare and pharmaceutical space.

Dr Carlo is currently a Medical Science Senior Advisor to the Italian Ministry of Health and an Adjunct Professor of Pharmacology at three universities in Italy.

The real-time software company claims it will develop innovative educational and communication models in various healthcare market segments by integrating its core technologies.

“Our ambition is to become a market reference point as leaders in the behavioural simulation immersive training field, leveraging Vection’s virtual reality, augmented reality, motion capture, morphing and avatar-based solutions,” Vection Healthcare CEO Dr Carlo Centemeri said.

“We have now secured the full commitment of Dr Centemeri and his team, leading market experts with unrivalled senior experience and network in this vertical – a strong endorsement of the company’s ability to attract the best talent key for the company’s growth,” Vection Managing Director Gianmarco Biagi said.

In the last few months, Vection has honed in on its international growth strategy which involves expanding into different sectors. At the end of last year, it stepped into the agri-food industry when it inked an agreement with popular Italian tomato brand Mutti, for its augmented reality (AR) solution.

Vection also brought its AR technologies to the global arts and cultural scene last November when it partnered with an Italian start-up company.

“The company’s management anticipates to significantly progress the next milestones in its verticalisation growth strategy in the short-term, ensuring unrivalled acceleration in the industry,” Gianmarco concluded.

Vection expects opportunities for its new division to start coming to fruition from next month.

Company shares are up 3.13 per cent and trading at 9.9 cents at 11:27 am AEDT.

VR1 by the numbers
More From The Market Online

Iress (ASX: IRE) strikes deal with Bain Capital for UK Mortgage Business Sale

Iress (ASX:IRE) has entered into a binding agreement to sell its UK Mortgage business to Bain…

Dotz Nano advances climate solutions with ‘Dotz Earth’

Dotz Nano is a leading developer of innovative climate and industrial technologies – and it's got…
The Market Online Video

Orcoda welcomes Maree Adshead as Non-Executive Director

Orcoda (ASX:ODA) has welcomed Maree Adshead as an independent Non-Executive Director.